维尔生物技术 VIR
$12.21 +$1.19 (+10.80%)
休市 · Nov 7, 5:10 am ET · 最新盘后价 $12.32 +0.91%
开盘$11.30
昨收$11.02
当日区间$11.30 – $12.45
成交量1.90M
市值$2.09B
市盈率（TTM）–
股息率–
VIR 相关新闻
匹配 Vir Biotechnology 或代码 VIR 的头条新闻，按最新排序。
- Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $17 负面
- Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
- H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
- BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $15 负面
- A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30
- A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $18 to $30
- Insiders Of Vir Biotechnology Make A Tidy Sum Selling At US$8.85
- Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)
- Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $27 正面
- Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30
- A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30
- Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $23 负面
- Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
- Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating
- BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16
暂无评论——快来第一个聊聊 VIR。